Wedbush Adjusts Ascendis Pharma A/S Price Target to $200 From $192, Maintains Outperform Rating
Wedbush Adjusts Ascendis Pharma A/S Price Target to $200 From $192, Maintains Outperform Rating
Wedbush將Ascendis Pharma A/S的目標股價從192美元調整至200美元,維持跑贏大盤的評級
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊